Palovarotene | Radio Compass News

US FDA approves French drugmaker Ipsen`s rare bone disorder drug

17 Aug 2023 //

REUTERS

Ipsen says EC rejects marketing authorization for bone disorder drug

19 Jul 2023 //

REUTERS

FDA adcomm votes in favor of Ipsen`s fibrodysplasia drug

29 Jun 2023 //

ENDPTS

Ipsen announces +ve outcome of FDA Advisory Committee on investig. palovarotene

28 Jun 2023 //

GLOBENEWSWIRE

FDA reviewers on Ipsen`s potential ultra-rare disease drug

27 Jun 2023 //

ENDPTS

Ipsen receives CHMP negative opinion, following re-examination of FOP treatment

26 May 2023 //

GLOBENEWSWIRE

Ipsen’s rare disease drug palovarotene knocked back in EU

28 Jan 2023 //

BUSINESSWIRE

Ipsen receives Complete Response Letter for palovarotene

24 Dec 2022 //

PRESS RELEASE

Ipsen faces yet another delay for rare disease drug in US

26 Oct 2022 //

PHARMAPHORUM

FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug

22 Aug 2022 //

ENDPTS

Ipsen Announces U.S. FDA Priority Review for palovarotene NDA

28 Jun 2022 //

BUSINESSWIRE

Health Canada Approves Ipsen’s Sohonos for Fibrodysplasia Ossificans Progressiva

24 Jan 2022 //

BUSINESSWIRE

Ipsen Announces Withdrawal of Palovarotene NDA

13 Aug 2021 //

BUSINESSWIRE

A $1B-plus drug stumbles into another big PhIII setback

28 Jan 2020 //

END PTS

FDA hits Ipsen`s $1B drug with clinical hold over safety signal

07 Dec 2019 //

FIERCE BIOTECH

Ipsen bags Blueprint drug to move deeper into ultra-rare disease

16 Oct 2019 //

FIERCE BIOTECH

Ipsen & Blueprint Medicines Announce Excl. Global License Agreement for BLU-782

16 Oct 2019 //

BUSINESSWIRE

Ipsen buys rare disease group Clementia in $1.3bn deal

26 Feb 2019 //

PRESS RELEASE

With Clear FDA Path, Clementia Raises $70.2M

31 Oct 2018 //

BIOCENTURY

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass

US FDA approves French drugmaker Ipsen`s rare bone disorder drug

Ipsen says EC rejects marketing authorization for bone disorder drug

FDA adcomm votes in favor of Ipsen`s fibrodysplasia drug

Ipsen announces +ve outcome of FDA Advisory Committee on investig. palovarotene

FDA reviewers on Ipsen`s potential ultra-rare disease drug

Ipsen receives CHMP negative opinion, following re-examination of FOP treatment

Ipsen’s rare disease drug palovarotene knocked back in EU

Ipsen receives Complete Response Letter for palovarotene

Ipsen faces yet another delay for rare disease drug in US

FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug

Ipsen Announces U.S. FDA Priority Review for palovarotene NDA

Health Canada Approves Ipsen’s Sohonos for Fibrodysplasia Ossificans Progressiva

Ipsen Announces Withdrawal of Palovarotene NDA

A $1B-plus drug stumbles into another big PhIII setback

FDA hits Ipsen`s $1B drug with clinical hold over safety signal

Ipsen bags Blueprint drug to move deeper into ultra-rare disease

Ipsen & Blueprint Medicines Announce Excl. Global License Agreement for BLU-782

Ipsen buys rare disease group Clementia in $1.3bn deal

With Clear FDA Path, Clementia Raises $70.2M